You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: November 5, 2024

CLINICAL TRIALS PROFILE FOR CARBOPROST TROMETHAMINE


✉ Email this page to a colleague

« Back to Dashboard


All Clinical Trials for CARBOPROST TROMETHAMINE

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00891150 ↗ Oxytocin to Decrease Blood Loss During Cesarean Section Completed American University of Beirut Medical Center N/A 2012-07-01 The goal of this study is to determine the best dose of a drug called oxytocin, that is usually used to stop bleeding during a delivery, when used during a cesarean delivery. It will be administered during cesarean section in order to decrease the amount blood loss. The investigators are proposing to have 3 groups of subjects each given a different safe dose of oxytocin and then to assess the effectiveness of each regimens on the amount blood lost during cesarean sections.This will let use know which is the best lowest dose needed.
NCT02722356 ↗ Outcomes After the Implementation of a New Oxytocin Protocol Completed C.R.Darnall Army Medical Center N/A 2016-04-01 The proposed study is a prospective, randomized, active control, open label study. One hundred sixty subjects undergoing elective cesarean section will be randomly assigned to one of two groups (n = 80 per group): the oxytocin protocol group or the standard practice group. The oxytocin protocol group will receive oxytocin boluses along with a regulated infusion according to a stepwise algorithm following delivery of the placenta. The standard practice group will receive oxytocin via a free flowing ("wide-open") infusion with a concentration of 30 IU per 500 mL of 0.9% normal saline following the delivery of the placenta. Primary outcomes include uterine tone (adequate or inadequate) as assessed by the surgeon, amount of time required to establish adequate uterine tone following the delivery of the infant, total dose of oxytocin required to establish adequate uterine tone, and total calculated blood loss based on pre-operative and post-operative hematocrit concentrations. Secondary outcomes include total estimated blood loss as agreed upon by the surgeon and the anesthesia provider, use of additional uterotonic drugs, mean arterial pressure, and incidence of oxytocin side effects (nausea, chest tightness/pain, and ST-segment changes).
NCT05518812 ↗ Carboprost (Hemabate) for Fibroid Resection Recruiting Northwestern University Early Phase 1 2022-07-12 The purpose of this research study is to determine if low-dose (i.e., a fraction of what is commonly used) carboprost (Hemabate) helps facilitate fibroid removal (myomectomy).
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for CARBOPROST TROMETHAMINE

Condition Name

Condition Name for CARBOPROST TROMETHAMINE
Intervention Trials
Complications; Cesarean Section 2
Adverse Reaction to Oxytocin 1
Fibroid Uterus 1
Gynecologic Disease 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for CARBOPROST TROMETHAMINE
Intervention Trials
Leiomyoma 1
Hemorrhage 1
Myofibroma 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for CARBOPROST TROMETHAMINE

Trials by Country

Trials by Country for CARBOPROST TROMETHAMINE
Location Trials
Lebanon 1
United States 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for CARBOPROST TROMETHAMINE
Location Trials
Illinois 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for CARBOPROST TROMETHAMINE

Clinical Trial Phase

Clinical Trial Phase for CARBOPROST TROMETHAMINE
Clinical Trial Phase Trials
N/A 2
Early Phase 1 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for CARBOPROST TROMETHAMINE
Clinical Trial Phase Trials
Completed 2
Recruiting 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for CARBOPROST TROMETHAMINE

Sponsor Name

Sponsor Name for CARBOPROST TROMETHAMINE
Sponsor Trials
American University of Beirut Medical Center 1
C.R.Darnall Army Medical Center 1
Northwestern University 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for CARBOPROST TROMETHAMINE
Sponsor Trials
Other 2
U.S. Fed 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.